Target intelligence / Profile preview

Meibomian gland ductal obstruction

Molecular classification
Other
01

Overview

"Meibomian gland ductal obstruction relief by physical expression" is not a molecular target, receptor, enzyme, or protein. Instead, it refers to a **therapeutic procedure** used to treat obstructive meibomian gland dysfunction (MGD), which is the most common cause of evaporative dry eye disease. The procedure involves physically expressing the contents of blocked meibomian glands—either manually or using devices—sometimes in combination with heat therapy. This mechanical intervention aims to clear obstructions within the ducts of the meibomian glands, restore normal oil flow into the tear film, stabilize tear film quality, and relieve symptoms such as ocular irritation and dryness[1][2][4][8]. Physical expression can be performed alone or after other treatments like warm compresses or vectored thermal pulsation systems (e.g., LipiFlow). More advanced techniques include **meibomian gland probing**, which uses a fine probe to mechanically open blocked ducts under local anesthesia[1][2]. These interventions are often combined with medical therapies such as topical antibiotics (azithromycin), oral antibiotics (doxycycline), corticosteroids for inflammation control, and at-home lid hygiene regimens[5][7]. This entry is not a canonical molecular target but rather describes a clinical intervention for an anatomical/functional abnormality; therefore, **is_incorrect** should be set to true. > "Manual expression...involves applying pressure to the eyelids to express oil from the glands. Successful meibomian gland expression helps increase the quality of oil production...and decrease dry eye." [8] > "Meibomian gland probing...has emerged as a pivotal intervention in managing obstructive MGD...[it] uses a wired probe to remove obstructions through natural orifices..." [1] In summary: this term does not refer to any specific molecule/receptor/protein but rather describes an interventional approach for treating an anatomical blockage in eyelid glands.

Other names
Meibomian gland obstructionObstructive meibomian gland dysfunction (OMGD)MGD with ductal blockage
02

Mechanism of action

Anti-inflammatory action (for antibiotics and corticosteroids)

03

Biological functions

Other
04

Disease associations

InflammationOther
05

Safety considerations

Pain or discomfort during physical expression or probing[5]Temporary conjunctival congestion and ocular burning symptoms after some procedures[3]
06

Interacting drugs

Azithromycin

2 more in the full profile.

Beyond the preview

Go deeper on Meibomian gland ductal obstruction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meibomian gland ductal obstruction.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call